Fosaprepitant Dimeglumine bulk supplier for pharma manufacturers

Fosaprepitant Dimeglumine 150 mg/vial Suppliers & Bulk Manufacturers

Available Forms: Injection (IV)

Available Strengths: 150 mg/vial

Reference Brands: Emend® IV (EU & US)

Fosaprepitant dimeglumine 150 mg powder for IV infusion, an NK1 antagonist prodrug used with a 5-HT3 antagonist and dexamethasone to prevent chemotherapy nausea. For hospitals, importers and distributors.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Fosaprepitant Dimeglumine? List it or send an offer →

Product Description:

Fosaprepitant dimeglumine is a water-soluble phosphorylated prodrug of aprepitant. Within about 30 minutes of infusion it is converted to aprepitant, which blocks neurokinin-1 (NK1) receptors for substance P in the brain areas that drive vomiting. This page covers the 150 mg single-dose vial of freeze-dried powder. The intravenous form lets oncology day units give the NK1 component once, with the rest of the premedication, instead of a three-day oral capsule course.

It is used with a 5-HT3 antagonist and dexamethasone to prevent acute and delayed nausea and vomiting with highly emetogenic chemotherapy, such as cisplatin regimens, and with moderately emetogenic chemotherapy. The dose is infused over 20 to 30 minutes, about half an hour before chemotherapy. Aprepitant moderately inhibits CYP3A4, so the oral dexamethasone dose is usually reduced. It can weaken hormonal contraceptives for several weeks, and patients on warfarin need INR checks. Infusion-site reactions, including thrombophlebitis, and hypersensitivity, including anaphylaxis, have been reported.

Sourcing notes. Generic versions are registered in many markets, usually on a dossier showing equivalent aprepitant exposure. The powder is reconstituted with sodium chloride 0.9% and diluted before infusion. Check the label for storage, as the originator vial is kept at 2-8°C while some generics differ. Ask for a CoA per batch with assay, impurities, sterility and endotoxin, a GMP certificate and CoPP, and zone IVb stability data for hot climates. It is prescription-only. Give vial numbers, required shelf life on arrival and whether you need a CTD or ACTD dossier.

Fosaprepitant Dimeglumine — third party manufacturing & bulk supply

Fosaprepitant Dimeglumine 150 mg/vial is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Fosaprepitant Dimeglumine is supplied as Injection (IV) — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Fosaprepitant Dimeglumine listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Fosaprepitant Dimeglumine →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Fosaprepitant dimeglumine injection is used for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin, and moderately emetogenic chemotherapy. It is administered intravenously as part of combination antiemetic therapy.

Fosaprepitant dimeglumine injection is made from fosaprepitant dimeglumine, which is a prodrug of aprepitant. It is a neurokinin-1 (NK1) receptor antagonist that works by blocking the action of substance P in the brain, thereby preventing chemotherapy-induced nausea and vomiting.

The most well-known trade name is Emend for Injection.

Emend for Injection is marketed by Merck & Co., Inc. Generic fosaprepitant dimeglumine injection is also manufactured by multiple pharmaceutical companies worldwide depending on regulatory approvals.

The generic name is fosaprepitant dimeglumine.

The brand name is Emend for Injection.

Fosaprepitant dimeglumine injection is manufactured in GMP-certified pharmaceutical facilities in the United States, Europe, India, and other regulated markets depending on the marketing authorization holder and supplier. Specific manufacturing locations vary by brand and batch.